Clinical characteristics according to CD56 expression
| Characteristics . | CD56+ ALCL . | CD56−ALCL . | P value . |
|---|---|---|---|
| Total | 25 | 115 | |
| Age (y), median (range) | 39 (4-85) | 29 (1-85) | .14 |
| Sex (male/female) | 17/8 | 78/37 | .99 |
| Stage | .31 | ||
| I | 6 (24%) | 9 (8%) | |
| II | 4 (16%) | 25 (22%) | |
| III | 5 (20%) | 31 (27%) | |
| IV | 10 (40%) | 50 (44%) | |
| PS | .99 | ||
| 0 | 12 (48%) | 51 (46%) | |
| 1 | 5 (20%) | 33 (30%) | |
| 2 | 4 (16%) | 9 (8%) | |
| 3 | 3 (12%) | 9 (8%) | |
| 4 | 1 (4%) | 10 (9%) | |
| LDH > normal | 11 (44%) | 56 (51%) | .56 |
| B symptoms | 14 (58%) | 63 (56%) | .82 |
| Extranodal involvement | |||
| BM | 2 (8%) | 19 (17%) | .28 |
| Skin | 3 (12%) | 33 (29%) | .19 |
| Liver | 2 (8%) | 10 (9%) | .91 |
| Spleen | 2 (8%) | 16 (14%) | .43 |
| Bone | 6 (24%) | 7 (6%) | .005 |
| Lung | 5 (20%) | 11 (10%) | .13 |
| Mediastinum | 2 (8%) | 9 (8%) | .97 |
| ≧ 1 site | 16 (64%) | 72 (62%) | .90 |
| ≧ 2 sites | 8 (32%) | 28 (25%) | .46 |
| IPI | .63 | ||
| Low | 11 (44%) | 44 (40%) | |
| Low-intermediate | 3 (12%) | 36 (32%) | |
| High-intermediate | 7 (28%) | 18 (16%) | |
| High | 4 (16%) | 13 (12%) |
| Characteristics . | CD56+ ALCL . | CD56−ALCL . | P value . |
|---|---|---|---|
| Total | 25 | 115 | |
| Age (y), median (range) | 39 (4-85) | 29 (1-85) | .14 |
| Sex (male/female) | 17/8 | 78/37 | .99 |
| Stage | .31 | ||
| I | 6 (24%) | 9 (8%) | |
| II | 4 (16%) | 25 (22%) | |
| III | 5 (20%) | 31 (27%) | |
| IV | 10 (40%) | 50 (44%) | |
| PS | .99 | ||
| 0 | 12 (48%) | 51 (46%) | |
| 1 | 5 (20%) | 33 (30%) | |
| 2 | 4 (16%) | 9 (8%) | |
| 3 | 3 (12%) | 9 (8%) | |
| 4 | 1 (4%) | 10 (9%) | |
| LDH > normal | 11 (44%) | 56 (51%) | .56 |
| B symptoms | 14 (58%) | 63 (56%) | .82 |
| Extranodal involvement | |||
| BM | 2 (8%) | 19 (17%) | .28 |
| Skin | 3 (12%) | 33 (29%) | .19 |
| Liver | 2 (8%) | 10 (9%) | .91 |
| Spleen | 2 (8%) | 16 (14%) | .43 |
| Bone | 6 (24%) | 7 (6%) | .005 |
| Lung | 5 (20%) | 11 (10%) | .13 |
| Mediastinum | 2 (8%) | 9 (8%) | .97 |
| ≧ 1 site | 16 (64%) | 72 (62%) | .90 |
| ≧ 2 sites | 8 (32%) | 28 (25%) | .46 |
| IPI | .63 | ||
| Low | 11 (44%) | 44 (40%) | |
| Low-intermediate | 3 (12%) | 36 (32%) | |
| High-intermediate | 7 (28%) | 18 (16%) | |
| High | 4 (16%) | 13 (12%) |
See Table 1 footnote for explanation of abbreviations.